Details for New Drug Application (NDA): 204223
✉ Email this page to a colleague
NDA 204223 describes MORPHINE SULFATE, which is a drug marketed by Actavis Elizabeth, Impax Labs Inc, Nortec Dev Assoc, Strides Pharma, Teva Pharms Usa, Upsher Smith Labs, Hikma, Hospira, Hospira Inc, Icu Medical Inc, Intl Medication Sys, Specgx Llc, Watson Labs, Fresenius Kabi Usa, Ani Pharms, Chartwell Molecular, Nostrum Labs Inc, Padagis Us, Pharm Assoc, Rhodes Pharms, Tris Pharma Inc, Vistapharm, Winder Labs Llc, Dava Pharms Inc, Dr Reddys Labs Sa, Epic Pharma Llc, Nesher Pharms, Novel Labs Inc, Rising, Sun Pharm Inds Ltd, Sun Pharm Industries, Alkem Labs Ltd, Ingenus Pharms Nj, and Meridian Medcl Techn, and is included in sixty-two NDAs. It is available from twenty-eight suppliers. There are three patents protecting this drug. Additional details are available on the MORPHINE SULFATE profile page.
The generic ingredient in MORPHINE SULFATE is morphine sulfate. There are twenty-three drug master file entries for this compound. Thirty suppliers are listed for this compound. Additional details are available on the morphine sulfate profile page.
The generic ingredient in MORPHINE SULFATE is morphine sulfate. There are twenty-three drug master file entries for this compound. Thirty suppliers are listed for this compound. Additional details are available on the morphine sulfate profile page.
Summary for 204223
| Tradename: | MORPHINE SULFATE |
| Applicant: | Fresenius Kabi Usa |
| Ingredient: | morphine sulfate |
| Patents: | 3 |
Pharmacology for NDA: 204223
| Mechanism of Action | Full Opioid Agonists |
Medical Subject Heading (MeSH) Categories for 204223
Suppliers and Packaging for NDA: 204223
| Tradename | Generic Name | Dosage | NDA | Application Type | Supplier | National Drug Code | Package Code | Package |
|---|---|---|---|---|---|---|---|---|
| MORPHINE SULFATE | morphine sulfate | SOLUTION;INTRAMUSCULAR, INTRAVENOUS | 204223 | NDA | Fresenius Kabi USA, LLC | 63323-451 | 63323-451-01 | 25 VIAL, SINGLE-DOSE in 1 BOX (63323-451-01) / 1 mL in 1 VIAL, SINGLE-DOSE (63323-451-00) |
| MORPHINE SULFATE | morphine sulfate | SOLUTION;INTRAMUSCULAR, INTRAVENOUS | 204223 | NDA | Fresenius Kabi USA, LLC | 63323-452 | 63323-452-01 | 25 VIAL, SINGLE-DOSE in 1 BOX (63323-452-01) / 1 mL in 1 VIAL, SINGLE-DOSE (63323-452-00) |
Profile for product number 001
| Active Rx/OTC/Discontinued: | RX | Dosage: | SOLUTION;INTRAMUSCULAR, INTRAVENOUS | Strength | 2MG/ML (2MG/ML) | ||||
| Approval Date: | Oct 30, 2013 | TE: | RLD: | Yes | |||||
| Patent: | ⤷ Subscribe | Patent Expiration: | Mar 12, 2034 | Product Flag? | Y | Substance Flag? | Delist Request? | ||
| Patent: | ⤷ Subscribe | Patent Expiration: | Mar 12, 2034 | Product Flag? | Substance Flag? | Delist Request? | |||
| Patented Use: | MANAGEMENT OF CHRONIC PAIN IN PATIENTS REQUIRING OPIOID ANALGESIA | ||||||||
| Patent: | ⤷ Subscribe | Patent Expiration: | Mar 12, 2034 | Product Flag? | Substance Flag? | Delist Request? | |||
| Patented Use: | TREATMENT OF PAIN | ||||||||
Complete Access Available with Subscription
